A mixed blessing for liver transplantation patients - Rapamycin.

Liver transplantation (LT) is an effective treatment option for end-stage liver disease. Mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin, are widely used post LT. In this review, we focused on the anti-cancer activities and metabolic side effects of rapamycin after LT. The literature available on PubMed for the period of January 1999-September 2022 was reviewed. The key words were rapamycin, sirolimus, liver transplantation, hepatocellular carcinoma, diabetes, and lipid metabolism disorder. Rapamycin has shown excellent effects and is safer than other immunosuppressive regimens. It has exhibited excellent anti-cancer activity and has the potential in preventing hepatocellular carcinoma (HCC) recurrence post LT. Rapamycin is closely related to two long-term complications after LT, diabetes and lipid metabolism disorders. Rapamycin prevents HCC recurrence post LT in some patients, but it also induces metabolic disorders. Reasonable use of rapamycin benefits the liver recipients. Copyright © 2022 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.

Citation

Guang-Han Fan, Chen-Zhi Zhang, Feng-Qiang Gao, Xu-Yong Wei, Sun-Bin Ling, Kai Wang, Jian-Guo Wang, Shu-Sen Zheng, Mehrdad Nikfarjam, Xiao Xu. A mixed blessing for liver transplantation patients - Rapamycin. Hepatobiliary & pancreatic diseases international : HBPD INT. 2023 Feb;22(1):14-21

Mesh Tags

Substances

PMID: 36328894

search → result